HIV-associated Neurocognitive Disorder Market Size (7MM) Reached ~USD 14 Billion in 2024

The HIV-associated Neurocognitive Disorder Market Size is projected to grow at a robust CAGR during the study period (2020–2034). DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the HIV-associated Neurocognitive Disorder Market Landscape.

By analyzing historical data, current HIV-associated Neurocognitive Disorder Market Dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The HIV-associated Neurocognitive Disorder Market is increasingly guided by biomarker-driven strategies. HIV-associated Neurocognitive Disorder (HAND) refers to a spectrum of cognitive, behavioral, and motor impairments caused by the effects of HIV on the central nervous system, even when the virus is well-controlled with antiretroviral therapy. It ranges from mild cognitive difficulties—such as problems with memory, concentration, and decision-making—to more severe forms that affect daily functioning. HAND occurs because HIV can trigger chronic inflammation and neuronal damage in the brain, and although treatment reduces its severity, it remains a significant neurological complication for many people living with HIV.

DelveInsight’s report, “HIV-associated Neurocognitive Disorder Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the HIV-associated Neurocognitive Disorder Market landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines HIV-associated Neurocognitive Disorder Market Dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the HIV-associated Neurocognitive Disorder Market Outlook, drug uptake, treatment scenario, and epidemiology trends, click here: HIV-associated Neurocognitive Disorder Market Forecast

Some of the key facts of the HIV-associated Neurocognitive Disorder Market Report

• The leading HIV-associated Neurocognitive Disorder Companies, such as UMC Utrecht, Bruce Brew, University of Hawaii, and others.

• Promising HIV-associated Neurocognitive Disorder Therapies such as Eviplera, Maraviroc, Cenicriviroc, and others.

• The HIV-associated Neurocognitive Disorder Market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching multiple-stage HIV-associated Neurocognitive Disorder Pipeline products will significantly revolutionize the HIV-associated Neurocognitive Disorder Market Dynamics.

HIV-associated Neurocognitive Disorder Overview

HAND refers to a range of cognitive, behavioral, and motor impairments resulting from HIV’s effects on the central nervous system. It includes conditions from asymptomatic neurocognitive impairment (ANI) and mild neurocognitive disorder (MND) to the more severe HIV-associated dementia (HAD). HIV invades the brain early, infecting macrophages and microglia, which leads to neuroinflammation, neuronal injury, and disrupted synaptic function.

Get a Free sample for the HIV-associated Neurocognitive Disorder Market Report @ https://www.delveinsight.com/report-store/hiv-associated-neurocognitive-disorders-hand-market 

Key Trends in HIV-associated Neurocognitive Disorder Therapeutics Market

1. Growing Recognition of HAND as a Significant Unmet Need

Despite advances in antiretroviral therapy (ART), cognitive impairment continues to affect a substantial portion of people living with HIV. Growing clinical awareness and improved diagnostic practices are pushing HAND into the spotlight, driving demand for targeted therapeutic options.

2. Shift Toward Adjunctive and Neuroprotective Therapies

Researchers are increasingly exploring therapies beyond ART, focusing on neuroprotection, anti-inflammatory approaches, and agents that target neuronal repair. This shift reflects the understanding that viral suppression alone does not fully prevent or reverse HAND-related neurocognitive decline.

3. Rising Interest in Targeting Neuroinflammation

Chronic neuroinflammation remains a key driver of HAND pathology. Therapeutics aimed at modulating microglial activation, reducing cytokine release, and controlling oxidative stress are gaining momentum in early-stage research and pipeline programs.

4. Exploration of BBB-Penetrant Agents

Effective treatment of HAND requires therapies with strong penetration across the blood–brain barrier (BBB). There is increasing focus on developing ART regimens and novel molecules with improved CNS penetration to minimize HIV persistence within the brain.

5. Emergence of Biomarker-Driven Approaches

Biomarkers—such as neurofilament light chain (NfL), inflammatory markers, and neuroimaging signatures—are being evaluated for early detection, treatment monitoring, and personalized therapy. Biomarker integration is shaping clinical trial designs and guiding future research.

6. Integration of Cognitive Rehabilitation and Digital Therapeutics

Non-pharmacological interventions, including cognitive training platforms, digital cognitive assessments, and neurobehavioral rehabilitation strategies, are gaining relevance. These tools complement pharmacologic therapy and support long-term functional outcomes.

7. Increasing Clinical Trial Activity in Neuro-HIV Research

Pharma and academic collaborations are accelerating clinical research, with several candidates exploring anti-inflammatory, neuroprotective, and neuro-restorative mechanisms. The expanding pipeline reflects growing investment in addressing HAND’s longstanding therapeutic gaps.

8. Focus on Aging Populations with HIV

As people living with HIV live longer due to effective ART, age-related cognitive decline overlaps with HAND. This demographic shift is influencing market demand, research priorities, and therapeutic strategies tailored for older patients.

HIV-associated Neurocognitive Disorder Epidemiology

The HAND epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by diagnosed prevalent cases of HIV, diagnosed prevalent cases of HAND, type-specific cases of HAND, gender-specific cases of HAND, diagnosed prevalent cases of distal sensory polyneuropathy in HIV, and the treated eligible patient pool of HAND in the 7MM covering the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2020 to 2034.

HIV-associated Neurocognitive Disorder Epidemiology Segmentation:-

The HIV-associated Neurocognitive Disorder Market Report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into-

• HIV-associated Neurocognitive Disorder Diagnosed Prevalent Cases
• HIV-associated Neurocognitive Disorder Diagnosed Prevalent Cases
• HIV-associated Neurocognitive Disorder Type-specific Case
• HIV-associated Neurocognitive Disorder Gender-specific Cases
• HIV-associated Neurocognitive Disorder Diagnosed Prevalent Cases of Distal Sensory Polyneuropathy
• HIV-associated Neurocognitive Disorder Treated the Eligible Pool

Download the report to understand which factors are driving HIV-associated Neurocognitive Disorder Epidemiology trends @ HIV-associated Neurocognitive Disorder Epidemiology Forecast

HIV-associated Neurocognitive Disorder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential HIV-associated Neurocognitive Disorder drugs recently launched in the HIV-associated Neurocognitive Disorder market or expected to get launched during the study period. The analysis covers HIV-associated Neurocognitive Disorder Market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the HIV-associated Neurocognitive Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

HIV-associated Neurocognitive Disorder Companies and Therapies

• UMC Utrecht: Eviplera
• Bruce Brew: Maraviroc
• University of Hawaii: Cenicriviroc

To know more about HIV-associated Neurocognitive Disorder Companies working in the treatment market, visit @ HIV-associated Neurocognitive Disorder Clinical Trials and Therapeutic Assessment

HIV-associated Neurocognitive Disorder Market Drivers

1. Rising Prevalence of HIV and Longer Patient Survival

With advancements in antiretroviral therapy (ART), individuals with HIV are living longer. This increased lifespan raises the likelihood of developing neurocognitive complications such as HAND, driving the demand for improved diagnosis, monitoring, and treatment options.

2. Growing Awareness of Neurocognitive Complications in HIV Patients

Healthcare professionals are increasingly recognizing HAND as a significant comorbidity in HIV-positive populations. This shift in awareness is leading to earlier screening, proactive management, and the need for more effective therapeutic solutions.

3. Limitations of Current Treatment Options

Existing ART regimens can reduce viral load but have limited effectiveness in addressing the neurological impact of HIV. The lack of targeted therapies for neuroinflammation, neuronal injury, and cognitive impairment creates opportunity for innovative drugs, boosting R&D activities.

4. Advancements in Neurodiagnostic Tools

Progress in imaging technologies, cognitive assessments, biomarkers, and CSF-based diagnostics is improving the detection and characterization of HAND. Enhanced diagnostic capabilities support better disease management and expand the potential market for emerging therapies.

5. Increased Research Focus on Neuroinflammation and CNS Penetration

There is a growing emphasis on developing therapies capable of crossing the blood–brain barrier (BBB), targeting neuroinflammation, and preventing synaptic dysfunction. This research momentum is fueling innovation in drug development pipelines.

6. High Unmet Medical Need

Despite significant scientific progress in HIV care, HAND remains underdiagnosed and undertreated. The persistent unmet need for effective neuroprotective, anti-inflammatory, and cognitive-enhancing therapies is a major driver motivating pharmaceutical companies and academic researchers.

HIV-associated Neurocognitive Disorder Market Barriers

1. Limited Understanding of Pathophysiology

Despite decades of research, the complex mechanisms driving HAND—ranging from chronic inflammation and viral persistence to neuronal injury—are not fully understood. This knowledge gap limits the development of targeted therapies and slows innovation.

2. Lack of FDA-Approved Therapies Specifically for HAND

Currently, no dedicated therapeutics exist for treating HAND. Management primarily relies on antiretroviral therapy (ART), which controls viral replication but does not adequately address neurocognitive decline. The absence of approved treatment options remains a major barrier to market growth.

3. Challenges in Early Diagnosis and Screening

HAND often presents with subtle cognitive symptoms that mimic aging or psychiatric disorders. Limited use of neuropsychological testing in routine HIV care, coupled with underreporting of early symptoms, contributes to diagnostic delays and underestimation of the true patient population.

4. Poor Penetration of Antiretroviral Drugs Into the CNS

Many ART regimens struggle to achieve optimal concentrations within the central nervous system. This allows persistent viral reservoirs and neuroinflammation to continue, reducing the effectiveness of existing management approaches and highlighting an unmet need for CNS-penetrant treatments.

5. High Heterogeneity of the Patient Population

HAND severity ranges from asymptomatic impairment to dementia, complicating clinical trial design and endpoint selection. Variability in patient backgrounds, comorbidities, and ART adherence adds further complexity for drug developers and researchers.

6. Limited Awareness Among Patients and Providers

Neurocognitive symptoms are frequently attributed to stress, fatigue, or aging rather than HAND. Low awareness among both patients and healthcare professionals results in underdiagnosis, reduced intervention rates, and less demand for emerging therapeutics.

Scope of the HIV-associated Neurocognitive Disorder Market Report

• Coverage- 7MM

• Study Period-2020-2034

• HIV-associated Neurocognitive Disorder Companies- UMC Utrecht, Bruce Brew, University of Hawaii, and others.

• HIV-associated Neurocognitive Disorder Therapies- Eviplera, Maraviroc, Cenicriviroc, and others.

• HIV-associated Neurocognitive Disorder Therapeutic Assessment: HIV-associated Neurocognitive Disorder current marketed and HIV-associated Neurocognitive Disorder emerging therapies

• HIV-associated Neurocognitive Disorder Market Dynamics: HIV-associated Neurocognitive Disorder market drivers and HIV-associated Neurocognitive Disorder market barriers

• HIV-associated Neurocognitive Disorder Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• HIV-associated Neurocognitive Disorder Unmet Needs, KOL’s views, Analyst’s views, HIV-associated Neurocognitive Disorder Market Access and Reimbursement

Discover more about therapies set to grab major HIV-associated Neurocognitive Disorder Market Share @ HIV-associated Neurocognitive Disorder Treatment Market

Table of Contents

1. Key Insights

2. Report Introduction

3. HIV-associated Neurocognitive Disorder Market Overview at a Glance

4. Executive Summary

5. Key Events

6. Disease Background and Overview

7. Methodology

8. Epidemiology and Patient Population

9. Patient Journey

10. Marketed Drugs

11. Emerging Drugs

12. HIV-associated Neurocognitive Disorder – 7MM Market Analysis

13. KOL Views

14. Unmet Needs

15. SWOT Analysis

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.